Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019

BMC Infectious Diseases

Table 3 A two-by-two contingency table for a drug-adverse event combination

	With an adverse event of interest	Other adverse events	Total
With a drug of interest	a	b	(a + b)
Without a drug of interest	c	d	(c + d)
Total	(a + c)	(b + d)	(a + b + c + d)

PRR = (a/[a + b])/(c/[c + d]) (criteria: PRR ≥ 2,χ2 ≥ 4, n ≥ 3); ROR = (a/c)/(b/d), 95% CI = eln^{(ROR) – 1.96(1/a+1/b+1/c+1/d)^0.5} (criteria: 95% CI > 1, n ≥ 2); IC = log2a*(a + b + c + d)/([a + b][a + c]), IC025 = e^{ln(IC)–1.96(1/a+1/b+1/c+1/d)^0.5} (criteria:IC025 > 0); EBGM = a*(a + b + c + d)/([a + b][a + c]), EBGM05 = e^{ln(EBGM)–1.64(1/a+1/b+1/c+1/d)^0.5} (criteria: EBGM05 > 2, n > 0). CI confidence interval, n indicates the number of co-occurrences, χ2 chi-squared, IC information component, IC025 the lower limit of the 95% two-sided CI of the IC, EBGM05 the lower limit of the 90% one-sided CI of the EBGM

ISSN: 1471-2334